| Literature DB >> 35401201 |
Liu-Ying Li1, Chuan-Tao Zhang2, Feng-Ya Zhu1, Gang Zheng3, Yu-Fei Liu2, Ke Liu3, Chen-Hui Zhang4, Hong Zhang4.
Abstract
Chronic obstructive pulmonary disease (COPD) is one of the major diseases threatening human life and health. According to the report released by the World Health Organization (WHO) in 2020, COPD has become the third leading cause of death in the world, featuring a sustainable growth of incidence rate as well as population age. The purpose of this review focuses on the advancement of bioactive natural compounds, such as baicalin, quercetin, resveratrol, and curcumin, which demonstrate promising therapeutic/interventional effects on CODP in vitro and in vivo. Information emphasizing on COPD was systematically collected from several authoritative internet databases including Web of Science, PubMed, Elsevier, Wiley Online Library, and Europe PMC, with a combination of keywords containing "COPD" and "natural small molecular compounds". The new evidence indicated that these valuable molecules featured unique functions in the treatment of COPD through various biological processes such as anti-inflammatory, anti-oxidant, anti-apoptosis, and anti-airway fibrosis. Moreover, we found that the promising effects of these natural compounds on COPD were mainly achieved through JAK3/STAT3/NF-κB and MAPK inflammatory signaling pathways, Nrf2 oxidative stress signaling pathway, and TGF-β1/Smad 2/3 fibrosis signaling pathway, which referenced to multiple targets like TNF-α, IL-6, IL-8, TIMP-1, MMP, AKT, JAK3, IKK, PI3K, HO-1, MAPK, P38, ERK, etc. Current challenges and future directions in this promising field are also discussed at the end of this review. For the convenience of the readers, this review is divided into ten parts according to the structures of potential natural small molecular compounds. We hope that this review brings a quick look and provides some inspiration for the research of COPD.Entities:
Keywords: alkaloid; chronic obstructive pulmonary disease; flavonoids; natural compounds; polyphenol
Year: 2022 PMID: 35401201 PMCID: PMC8988065 DOI: 10.3389/fphar.2022.821941
Source DB: PubMed Journal: Front Pharmacol ISSN: 1663-9812 Impact factor: 5.810
FIGURE 1The 10 kinds of natural small molecular compounds that have an effect on COPD.
FIGURE 2The biological processes and mechanisms of natural small molecular compounds in the treatment of COPD.
FIGURE 3The signaling pathways of natural small molecular compounds in the treatment of COPD.
The effects of flavonoid on COPD.
| Flavonoids | Sources | Models | Effects | Dose | Application | Ref |
|---|---|---|---|---|---|---|
| Baicalin | Scutellaria baicalensis Georgi |
| Inhibition of the NF-kB pathway | 20–80 mg/kg |
|
|
|
| 5–20 μM |
| ||||
| CS-induced inflammatory models in mice; CSE-induced inflammatory models in A549 cells | Modulating HDAC2/anti-inflammatory | 25–100 mg/kg |
|
| ||
| 10–100 μM |
| |||||
| CS-induced rat model of COPD | Anti-infammatory/anti-airway remodeling/antioxidant | 40–160 mg/kg |
|
| ||
| CS/CSE-induced airway inflammation in mice or human bronchial epithelial (HBE) cells | Anti-infammatory | 40–160 mg/kg |
|
| ||
| 10–40 μM |
| |||||
| CSE-induced MLE-12 cells; CS-induced COPD mice model | Regulation of HSP72-mediated JNK pathway | 25–100 mg/kg |
|
| ||
| 5–20 μmol/L |
| |||||
| Quercetin | Polygoni avicularis herba | CSE-induced muman monocytic U937 cells and peripheral blood mononuclear cells (PBMC) collected from patients with COPD | Increased AMPK activation and Nrf2 expression, and restored corticosteroid resistance | 10 μM |
|
|
| CSE-induced mice model/human airway epithelial NCI-H292 cells | Inhibiting the NF-κB pathway and EGFR phosphorylation | 25–50 mg/kg |
|
| ||
| 5–20 μM |
| |||||
| Primary human osteoblasts exposed to cigarette smoke medium (CSM) | Activation of the anti-oxidative enzymes HO-1 and SOD-1 | 25–100 μM |
|
| ||
| Elastase/lipopolysaccharide (LPS)-exposed mice | Negatively regulating MMP expression | 10 mg/kg |
|
| ||
| Rhinovirus-infected mice with COPD phenotype | Preventing progression of lung disease in COPD | 0.1% quercetin containing diet |
|
| ||
| Silymarin | Silybum marianum | CS-induced mice mode | Suppression of inflammation and oxidative stress by inhibiting the ERK/p38 MAPK pathway | 25–50 mg/kg |
|
|
| CSE-induced human bronchial epithelial cell line (BEAS-2B) model | Inhibition of autophagy and the ERK/p38 MAPK pathway | 10–40 μM |
|
| ||
| Silibinin | Silybum marianum | CS and LPS exposure-induced mice model | Inhibited the pulmonary fibrosis induced by CS via suppression of TGF-β1/Smad 2/3 signaling | 10–20 mg/kg |
|
|
| CS-/LPS-induced COPD model mice; CS condensate-stimulated H292 cells | Inhibition in ERK phosphorylation | 20–40 mg/kg |
|
| ||
| 6.25–50 μg/ml |
| |||||
| Icariin | Epimedium | CSE-exposed BEAS-2B cells model | Reversing Glucocorticoids (GC)resistance | 20–80 µM |
|
|
| CS-induced lung inflammation using BALB/c mice; CSE-exposed A549 epithelial cells | Ameliorated inflammation by suppressing NF-kB activation and modulating glucocorticoid receptor (GR) protein expression | 25–100 mg/kg |
|
| ||
| 10–100 µM |
| |||||
| Casticin | Vitex rotundifolia and Vitex agnus-castus | CS-induced C57BL/6 mice model | Inhibition of inflammatory cytokines and chemokines | 1–10 mg/kg |
|
|
| CS-exposed mice | Attenuated oxidative Stress and inflammation via inhibition of NF-ĸB | 10–30 mg/kg |
|
| ||
| Fisetin | Gleditsiae spina | Human airway epithelial cells | Inhibiting the TNF-α/NF-κB signaling pathway | 2.5–10 μM |
|
|
| CS-exposed mice | Up-regulation of Nrf2 expression | 50 mg/kg |
|
| ||
| Phloretin | Crotonis fructus; Rubi fructus | CS-induced mice model; CSE-induced NCI-H292 cells model | Inhibition of epidermal growth factor receptor (EGFR)/MAPK signaling pathways | 10–20 mg/kg |
|
|
| 1–10 μM |
| |||||
| Morin | Cudrania tricuspidata | CS-induced mice model | Anti-inflammation via inhibiting the P13K/ATK/NF-κB signaling pathway | 10–40 mg/kg |
|
|
| Oroxylin A | Scutellaria baicalensis Georgi | CS-stimulated BEAS-2B cells and RAW264.7 cells; CS-induced mice | Activating the Nrf2 signaling pathway | 15–60 mg/kg |
|
|
| 50–150 μM |
| |||||
| Hesperetin | Citrus reticulata | CSE-induced mice model | Regulation of SIRT1/PGC-1α/NFκ-B signaling axis | 25–50 mg/kg |
|
|
| CS- and urethane-induced lung cancer with COPD in mice | Preventing COPD progression to lung cancer | 25–100 mg/kg |
|
| ||
| Liquiritin apioside | Glycyrrhiza uralensis | CSE-induced cell injury in the A549 lung epithelial cell; CS-induced mice inflammation model | Inhibiting TGF-β and TNF-α expression and increasing levels of GSH | 3–30 mg/kg |
|
|
| 108–106 M |
| |||||
| Isoliquiriti-genin | liquorice | CS-induced mice model | Regulating the Nrf2 and NF-κB signaling pathways | 10–30 mg/kg |
|
|
| Chrysin | Flowers | CS-induced airway inflammation in mice | Inhibition of ERK and p38 phosphorylation | 10–20 mg/kg |
|
|
| Naringenin | Amacardi-um occidentale L | CS-induced mice model; CSE-exposed A549 cells | Suppression of NF-κB | 20–80 mg/kg |
|
|
|
|
FIGURE 4The bioactive natural compounds from flavonoid, polyphenol, and alkaloid.
The effects of polyphenol on COPD.
| Polyphenol | Sources | Models | Effects | Dose | Application | Ref | |
|---|---|---|---|---|---|---|---|
| Resveratrol | Various plants, nuts and fruits | CSE-induced HBE cell model | Anti-apoptotic effect through the activation SIRT1 and ORP150 | 20 μmol/L |
|
| |
| CSE-induced Human umbilical vein endothelial cells (HUVECs) model | Anti-apoptosis | 40 μM |
|
| |||
| CSE-induced HBE cells model | Reduced apoptosis | 20 μM |
|
| |||
| CS-induced mice model | Decreased NF-κB activity and the elevated HO-1 expression and activity | 1–3 mg/kg |
|
| |||
| CS- and LPS-induced lung inflammation in a mouse model of COPD | Activating SIRT1/PGC-1α signaling pathways | 50 mg/kg |
|
| |||
| Human bronchial smooth muscle cells (HASMCs) exposed to lipoteichoic acid (LTA) | Anti-inflammation | 10-6-10-4M |
|
| |||
| Lymphocytes isolated from patients with COPD | Inhibited the translocation of NF κB, and decreased TNF α | 12.5 μmol/l |
|
| |||
| Human airway smooth muscle cells | Anti-inflammatory | 10-7-10–3 M |
|
| |||
| Dendritic cells (DCs) from COPD patients | Inhibited dysfunction of dendritic cells (DCs) | 10 μmol/ml |
|
| |||
| Old mice with COPD induced by CS exposure and LPS instillation | Attenuated left ventricular remodeling | 25 mg/kg |
|
| |||
| Prematurely ageing telomerase null (terc−/−) mice | Slowed ageing-related degenerative changes in mouse lungs | 1 mg/kg |
|
| |||
| Curcumin | Curcuma longa | In mice model of COPD-like airway inflammation induced by non-typeable haemophilus influenzae exposure (NTHi) | Inhibition of inflammation and lung cancer progression | 0.2–2% |
|
| |
| LPS- and CS-induced COPD murine models; LPS-stimulated BEAS-2B cells | Inhibiting NF-κB Signaling and COX-2 | 100–200 mg/kg |
|
| |||
| 0.1–10 μmol/L |
| ||||||
| CSE-treated BEAS-2B cells; CS-induced COPD mice models | Modulating the PPARγ-NF-κB signaling pathway | 100 mg/kg |
|
| |||
| 2.5–7.5 mΜ |
| ||||||
| Patients with mild COPD | Reduced serum atherosclerotic low-density lipoprotein levels in patients with mild COPD | 180 mg |
|
| |||
| Mice model of COPD established by CSE combined with lipopolysaccharide | Up-regulation of PGC-1α/SIRT3 signaling pathway | 100 mg/kg |
|
| |||
|
| Restored corticosteroid function in monocytes exposed to oxidants by maintaining HDAC2 | 1–10,000 nM |
|
| |||
| CSE-induced mice model with COPD | Modulating HDAC2 expression and its effect on histone modification | 100 μM |
|
| |||
| Carvacrol | Zataria multiflora Boiss | Elastase-induced emphysema mice | Anti-inflammatory via suppression of NF-κB | 20 mg/kg |
|
| |
| Guinea pigs model of COPD induced by CSE | Attenuated systemic inflammation | 60–240 μg/ml |
|
| |||
| Guinea pigs model of COPD exposed to CS | Prevention of tracheal responsiveness and emphysema | 60–240 μg/ml |
|
| |||
| Guinea pigs model of COPD exposed to CS | Against lung inflammation and oxidative stress | 60–240 μg/ml |
|
| |||
| Gallic acid | Rheum palmatum L | Elastase (ET-) + LPS- induced COPD exacerbation like condition in mice model | Prevented the activation of NF κB and elevated the expression of Nrf2 | 200 mg/kg |
|
| |
| ET- and CS-induced mice model | Suppressed phosphorylation of p65NF-κB and IκBα along with down-regulation of IL-1β/TNF-α/KC/MIP-2/GCSF genes | 200 mg/kg |
|
| |||
| Paeonol | Paeonia suffruticosa | CS-induced mice model/CSE-induced HBE cell model | Inhibition of the MAPKs/NF-κB signaling | 10 mg/kg |
|
| |
| 0.05–0.4 mM |
| ||||||
The effects of alkaloids on COPD.
| Alkaloid | Sources | Models | Effects | Dose | Application | Ref | |
|---|---|---|---|---|---|---|---|
| Berberine | Coptidis Rhizoma | CS-induced mice model | Suppressed CS-induced NF-κB activation | 50 mg/kg |
|
| |
| CSE-induced airway inflammation in mice | Inhibition of TGF-β1/Smads signaling | 25 mg/kg |
|
| |||
| Mice exposed to CS | Inhibition of ERK and P38 pathway | 5–10 mg/kg |
|
| |||
| Tuberostemonine | Stemona tuberosa | CS-induced lung inflammation in mice | Suppressed inflammation | 1–10 mg/kg |
|
| |
| CS-induced mice model | Suppressed inflammation | 1–10 mg/kg |
|
| |||
| Matrine | Sophora flavescens Ait | CS-induced mice model | Inducing neutrophil apoptosis | 100 mg/kg |
|
| |
The effects of glycosides on COPD.
| Glycosides | Sources | Models | Effects | Dose | Application | Ref | |
|---|---|---|---|---|---|---|---|
| Ginsenoside Rg1 | Panax ginseng | CSE-induced COPD mice; Human embryonic lung fibroblasts exposed to CSE | Suppressed airway fibrosis | 20 mg/kg |
|
| |
| 40 μM |
| ||||||
| CSE-induced COPD mice and HBE cells model | Attenuated Pulmonary Epithelial-Mesenchymal Transition (EMT) | 5–20 mg/kg |
|
| |||
| 5–160 μM |
| ||||||
| Ginsenoside Rg3 | Panax ginseng | AECOPD murine model established by CS exposure and NTHi infection; CS- and NTHi stimulation on BEAS-2B | Inhibition of PI3K | 10–40 mg/kg |
|
| |
| 10–160 μM |
| ||||||
| Salidroside | Rhodiola rosea L | CS-induced COPD in mice | Mitigated skeletal muscle atrophy | 50–200 mg/kg |
|
| |
| CS-induced COPD in mice | Inhibition the MAPK/NF-kB pathway | 20–40 mg/kg |
|
| |||
| Piscroside C | Pseudolysimachion rotundum var. subintegrum | TNF-α-stimulated human airway epithelial cells (NCI-H292 cells) | Inhibited TNF-α/NF-κB pathway by suppression of PKCδ activity for TNF-RSC formation | 2.5–20 μM |
|
| |
| CS- and LPS-induced COPD mice model; TNF-stimulated human airway epithelial NCIH292 cells | Suppression of IKK/NF-κB activation | 15–30 mg/kg |
|
| |||
| 2.5–20 μM |
| ||||||
| Naringin | Grape fruit and citrus fruits | CS-induced COPD mice model | Anti-inflammatory | 20–80 mg/kg |
|
| |
| Paeoniflorin | Paeonia lactiflora | CS-exposed COPD mice model | Attenuated oxidative stress via an Nrf2-dependent mechanism | 40 mg/kg |
|
| |
| Forsythiaside | Forsythia suspensa | CS-induced mice model | Activating Nrf2 and inhibiting NF-κB signaling pathways | 15–60 mg/kg |
|
| |
| Platycodin D | Platycodon grandiflflorum | CS-induced mice model | Activating the Nrf2 signaling pathway | 20–80 mg/kg |
|
| |
| Saikosaponin a | Radix bupleuri | CS-induced mice model | Inhibited oxidant stress and inflammatory by activating the Nrf2 and inhibiting the NF-κB signaling pathway | 5–20 mg/kg |
|
| |
FIGURE 5The bioactive natural compounds from glycosides, terpenoids, and lacton.
The effects of terpenoids on COPD.
| Terpenoids | Sources | Models | Effects | Dose | Application | Ref | |
|---|---|---|---|---|---|---|---|
| Ursolic acid | Loquat leaves, glossy privet leaves, forsythia, Prunella vulgaris | CSE treated normal human bronchial epithelial (NHBE) cell model; mice model established by A549 cells in nude mice | Prevented development of lung cancer | 10 mg/kg |
|
| |
| 3.2–25 μmol/L |
| ||||||
| CS-induced mice emphysema model | Down-regulating PERK pathway and up-regulating Nrf2 pathway | 10–40 mg/kg |
|
| |||
| CS-induced emphysema mice | Alleviated airway-vessel remodeling and muscle consumption partly through IGF1 and TGF-β1/Smad2.3 signaling pathways | 10–40 mg/kg |
|
| |||
| CES-exposed mice model | Alleviated CSE-induced emphysema and airway remodeling | 10–40 mg/kg |
|
| |||
| Eucalyptol | Eucalyptus globulus | CS-induced COPD mice model | Promoted lung repair | 1–10 mg/kg |
|
| |
| CS-induced COPD mice model | Anti-inflammatory and antioxidant effects via attenuating NF-κB p65 subunit activation | 1–10 mg/ml |
|
| |||
| CS-induced COPD mice model | Against bacterial invasion through attenuating ciliated cell Damage and suppressing MUC5AC expression | 260 mg/kg |
|
| |||
| CS-induced COPD mice model | Mitigated lung injury by suppressing ICAM-1 gene expression | 260 mg/kg |
|
| |||
| Taraxasterol | Taraxacum officinale | CS-induced mice model; CSE- induced HBE cells model | Inhibiting oxidative stress and inflammatory responses | 2.5–10 mg/kg |
|
| |
| 3–12 μg/ml |
| ||||||
The effects of lactone on COPD.
| Lactone | Sources | Models | Effects | Dose | Application | Ref | ||
|---|---|---|---|---|---|---|---|---|
| Andrographolide | Andrographis paniculata | CSE-exposed RAW 264.7 cells | Inhibition of SIRT1/ERK signaling pathway | 1–40 µM |
|
| ||
| BEAS-2B cells exposed to CSE | Augmented Nrf2 antioxidant defense and facilitated autophagic flux blockade | 10–30 μM |
|
| ||||
| Human alveolar epithelial A549 cells exposed to CSE | Induction of microRNA-218 | 5 μM |
|
| ||||
| CSE-exposed bronchial epithelial cells (BEAS-2); CS-exposed mice as COPD model | Augmentation of Nrf2 activity | 0.1–1 mg/kg |
|
| ||||
| 30 μM |
| |||||||
| CS-exposed mice model | Activation of HO-1–mediated signaling | 1 mg/kg |
|
| ||||
| Artesunate | Artemisia annua L | CS-exposed COPD mice model; human bronchial smooth muscle cells exposure in CSE | Against airway inflammation and airway remodeling via PPAR-γ/TGF-β1/Smad2/3 signaling | 25–100 mg/kg |
|
| ||
| 1–100 μM |
| |||||||
| CSE-exposed BEAS-2; CS-exposed mice as COPD model | Anti-inflammatory and anti-oxidative | 10–100 mg/kg |
|
| ||||
| 30 μM |
| |||||||
| Alantolactone | Inula helenium L | CSE-exposed BEAS-2B and NHBE cells | Activation of Nrf2/HO-1 and inhibition of the NF-κB pathways | 1–10 μM |
|
| ||
| Sulforaphane | Cruciferous vegetables | Monocyte-derived macrophages (MDMs) from patients with COPD | Modulating the TLR pathway | 2.5–20 μmol/L |
|
| ||
The effects of acid on COPD.
| Acid | Sources | Models | Effects | Dose | Application | Ref |
|---|---|---|---|---|---|---|
| p-coumaric acid | Bambusae Caulis | A549 cells exposed to CSE to induce inflammatory process | Anti-inflammatory | 10–100 µM |
|
|
| CS-induced inflammatory mice model | Suppressed CS-induced pulmonary inflammation | 5–10 mg/kg |
|
| ||
| 3,4,5-Trihydroxycinnamic acid | ||||||
| Cinnamomum cassia Presl | COPD model elicited by CS and LPS; phorbol myristate acetate (PMA)-stimulated A549 or H292 airway epithelial cells | Down-regulation of MAPK (partial p38 and JNK)/NF-κB signaling and upregulation of NQO1 and SIRT1 expression | 20–40 mg/kg |
|
| |
| 5–50 µM |
| |||||
| Salvianolic acid B | Radix Salviae Miltiorrhizae | CS-induced mice model | Attenuated inflammation via activating Nrf-2 and inhibiting NF-κB activation | 6–25 mg/kg |
|
|
| Asiatic acid | Centella asiatica | CS-exposed mice model | Up-regulation of HO-1 and inhibition of the activation of MAPKs and NF-kB pathway | 15–30 mg/kg |
|
|
| Triterpene acids | Eriobotrya japonica | CS-induced mice model | Regulating the AMPK/Nrf2 and NFκB Pathways | 50–100 mg/kg |
|
|
FIGURE 6The bioactive natural compounds from acid, alcohol, carotenoid –and others.
The effects of alcohol on COPD.
| Alcohol | Sources | Models | Effects | Dose | Application | Ref | |
|---|---|---|---|---|---|---|---|
| Ergosterol | Cordyceps sinensis (C. sinensis) | CSE-induced COPD model both in 16HBE cells and Balb/c mice | Suppressed COPD inflammatory and oxidative stress and apoptosis through the suppression of NF-κB/p65 activation | 20–40 mg/kg |
|
| |
| 5–20 μM |
| ||||||
| CS-induced COPD mice model | Inhibiting the JAK3/STAT3/NF-κB pathway | 25–50 mg/kg |
|
| |||
| Betulin | Birch tree bark | CS-induced COPD mice model | Inhibiting the inflammatory response and oxidative stress possibly through the ROCK/NF-κB pathway | 20–40 mg/kg |
|
| |
| Linalool | Aromatic plants species | CS-induced COPD mice model | Against inflammation by inhibiting CS-induced NF-κB activation | 10–40 mg/kg |
|
| |
The effects of carotenoids on COPD.
| Carotenoid | Sources | Models | Effects | Dose | Application | Ref | |
|---|---|---|---|---|---|---|---|
| Lycopene | Tomatoes | CS-exposed mice model | Anti-oxidant and anti-inflammatory | 25–50 mg/kg |
|
| |
| J774A.1 (Macrophages) cells exposed to CSE; CS-exposed mice model | Anti-oxidant and anti-inflammatory | 25–50 mg/kg |
|
| |||
| 0.5–25 µM |
| ||||||
| Crocin | Crocus sativus L | CS-induced mice model | Activation of Nrf2 pathway | 50 mg/kg |
|
| |
| CS-exposed C57BL/6 mice model | Preventing the activation of PI3K/Akt mediated NF-κB inflammatory pathways | 50 mg/kg |
|
| |||
The effects of other compounds on COPD.
| Compound | Sources | Models | Effects | Dose | Application | Ref |
|---|---|---|---|---|---|---|
| Emodin | Rheum palmatum L | CS-induced lung injury in a mouse model | Enhancing the expression and activities of HO-1 and Nrf-2 | 20–40 mg/kg |
|
|
| Astragaloside IV | Astragalus mongholicus | CS-induced mice model; CSE-stimulated NHBE cells model | Inhibition of the JAK3/STAT3/NF-κB pathway | 10–40 mg/kg |
|
|
| 10–40 μM |
| |||||
| Polysaccharides from Dendrobium huoshanense | Dendrobium huoshanense | CS-induced mice model | Inhibition of the NF-κB and MAPK signaling pathways | 100–400 mg/kg |
|
|
| FA-1 | Prunus mume | CSE-induced immortalized HBE cells and normal human epidermal keratinocytes (NHEK) | Augmenting ALDH and DNA repair | 150 nM |
|
|
| Houttuynia | Houttuynia cordata Thunb | Mice model of COPD established by smoking combined with intratracheal instillation of LPS | Inhibiting the activation of the TLR4/MyD88/NF-κB (p65) signaling pathway | 5–25 mg/kg |
|
|
| Sodium Houttuyfonate | Houttuynia cordata Thunb | CS- and LPS-induced mice model | Suppressing the TLR4/NF-κB pathway | 24.3 mg/kg |
|
|
| Schisandrin B | Schisandra chinensis | CS-induced mice model | Activating Nrf2 and inhibiting the NF-κB signaling pathway | 20–80 mg/kg |
|
|